NCT00001351

Evaluation and Long-Term Follow-up of Patients With Inflammatory Disorders

ENROLLING BY INVITATION Last updated 18 December 2025

What this trial tests

trial in Inflammation in 500 participants. Enrolling by invitation.

Timeline

1 June 1993

Quick facts

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 June 1993
Sites	1 location across United States

Conditions studied

• Inflammation — all drugs for Inflammation →

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Who can join

2 and older, any sex, with Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate inflammatory diseases and disorders. Inflammation is the body s immune response to many things, including infections and other acute or chronic irritants. It may also be a sign of abnormal immune function. This study will allow evaluation and long-term follow-up of such disorders to:

* Establish and maintain a group of patients that may be eligible for other NIAID protocols.
* Provide clinical training and experience for NIAID fellows.
* Provide a mechanism for NIAID staff to maintain their clinical skills.
* Serve as a starting point for new investigations of syndromes not currently under study.

Patients between 1 and 80 years of age with acute or chronic inflammation, including but not limited to viral, fungal or bacterial infections, or abnormal immune responses may be eligible for this study. Immediate family members of patients may also be enrolled for preliminary examination to see if they are affected in any way that may warrant further investigation.

All patients and family members will have a history, physical examination and laboratory tests. Depending on the results, family members may require additional tests. Patients will have additional diagnostic tests indicated for their specific disease, according to accepted medical standards. These may include routine blood and urine tests, X-rays or other imaging studies, body fluid or tissue cultures, skin tests for allergic or immune responses, and others as needed.

Treatments will include only medications approved by the Food and Drug Administration according to accepted dose schedules and delivery methods.

Patients may be requested to donate extra blood for research studies. No more than 450 cc (30 tablespoons) will be drawn from adults within a 6-week period, and no more that 7 cc (1/2 tablespoon) from children under 18 years of age in the same time period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.